FDA has granted tentative approval to Accord Healthcare, Inc.’s ANDA for methylphenidate hydrochloride tablets, a generic version of the drug known by the brand name Ritalin, allowing the company to commence sales following the patent expiry of the reference product to effectively increase competition in the ADHD treatment market.